| Schedule of inventory, current |
At June 30, 2026 and December 31, 2025, the Company's net inventories consisted of the following: | | | | | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | | | | | | Raw materials and work in progress | | $ | 9,679,198 | | | $ | 9,832,293 | | | | | | | | Finished goods | | 4,932,630 | | | 5,646,315 | | | Total | | 14,611,828 | | | 15,478,608 | | | Non-current inventory | | (40,879) | | | (40,879) | | | Total Inventory | | 14,570,949 | | | 15,437,729 | | | Discontinued operations | | (14,541,014) | | | (15,407,794) | | | Net inventory from continuing operations | | $ | 29,935 | | | $ | 29,935 | |
|
| Schedule of inventory, noncurrent |
At June 30, 2026 and December 31, 2025, the Company's non-current inventories consisted of the following: | | | | | | | | | | | | | June 30, 2026 | | December 31, 2025 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Ifetroban raw materials | 40,879 | | | 40,879 | | | | | | | | | | | | | | | | | | | | | | | Total non-current inventories classified as continuing operations | $ | 40,879 | | | $ | 40,879 | |
|